Eugia Drug Patent Portfolio
Eugia owns 1 orange book drug protected by 1 US patent Given below is the list of Eugia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9662342 | Formulations of cyclophosphamide liquid concentrate | 26 Jun, 2035 | Active |
Latest Legal Activities on Eugia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eugia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 May, 2024 | US10849916 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10993952 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 12 Jul, 2022 | US11382923 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Jul, 2022 | US11382923 |
|
Email Notification
Critical
| 23 Jun, 2022 | US11382923 |
|
Issue Notification Mailed
Critical
| 22 Jun, 2022 | US11382923 |
| Dispatch to FDC | 08 Jun, 2022 | US11382923 |
|
Application Is Considered Ready for Issue
Critical
| 08 Jun, 2022 | US11382923 |
|
Issue Fee Payment Received
Critical
| 06 Jun, 2022 | US11382923 |
|
Issue Fee Payment Verified
Critical
| 06 Jun, 2022 | US11382923 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 06 May, 2022 | US11382923 |
|
Email Notification
Critical
| 06 May, 2022 | US11382923 |
| Filing Receipt - Updated | 06 May, 2022 | US11382923 |
| Miscellaneous Incoming Letter | 03 May, 2022 | US11382923 |
|
Email Notification
Critical
| 25 Apr, 2022 | US11382923 |
Eugia's Family Patents
Recent FDA approvals and tentative approvals for Eugia
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Carfilzomib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 25 Nov, 2022 |
| Palbociclib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 07 Jul, 2022 |
| Nintedanib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 12 May, 2022 |
Eugia Drug List
Given below is the complete list of Eugia's drugs and the patents protecting them.
1. Cyclophosphamide
Cyclophosphamide is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9662342 | Formulations of cyclophosphamide liquid concentrate |
26 Jun, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cyclophosphamide's drug page